SCHEMBL4922707

SCHEMBL4922707

CCOC(=O)c1[nH]c2ccc(NS(=O)(=O)c3ccc(C(C)(C)C)cc3)cc2c1-c1ccc(C)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 5/20 0.56
BRD4 O60885 1/20 0.50
ACR P10323 1/20 0.49
MAPT P10636 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
TP53 P04637 2/20 0.48
THRB P10828 1/20 0.48
ALDH1A1 P00352 4/20 0.47
HPGD P15428 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 2/20 0.47
XBP1 P17861 1/20 0.47
HSD17B10 Q99714 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALOX15 P16050 1/20 0.45
MAPK1 P28482 1/20 0.45
LMNA P02545 2/20 0.44
RECQL P46063 1/20 0.44
SERPINE1 P05121 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4926673 0.93 ALDH1A1 (0.55) HIF1ABRD4ACRMAPTSMN1; SMN2
SCHEMBL4586922 0.93 ALDH1A1 (0.56) HIF1ABRD4MAPTSMN1; SMN2TP53
SCHEMBL4927908 0.92 HIF1A (0.54) HIF1ABRD4MAPTSMN1; SMN2TP53
SCHEMBL4923602 0.91 HIF1A (0.53) HIF1ABRD4ACRMAPTSMN1; SMN2
SCHEMBL4932283 0.91 HIF1A (0.54) HIF1ABRD4ACRMAPTSMN1; SMN2
Dimethylamine SCHEMBL4923606 0.91 ALDH1A1 (0.55) HIF1ABRD4MAPTSMN1; SMN2TP53
SCHEMBL4929352 0.91 HIF1A (0.54) HIF1ABRD4MAPTSMN1; SMN2TP53
SCHEMBL13880195 0.88 BRD4 (0.54) HIF1ABRD4MAPTALDH1A1HPGD
SCHEMBL3947323 0.88 BRD4 (0.54) HIF1ABRD4MAPTALDH1A1HPGD
SCHEMBL5151934 0.88 ALDH1A1 (0.56) HIF1ABRD4MAPTSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004268-A1 INHIBITORS OF SOLUBLE ADENYLATE CYCLASE NGUYEN DUY 2008-01-03 US disclosed
US-20060074084-A1 Inhibitors of soluble adenylate cyclase BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004268-A1 INHIBITORS OF SOLUBLE ADENYLATE CYCLASE ADCY1, ADCY2, ADCY5 HIF1A 1888/4885BRD4 3928/4885ACR 3137/4885
US-20060074084-A1 Inhibitors of soluble adenylate cyclase ADCY1, ADCY2, ADCY5 HIF1A 1888/4885BRD4 3928/4885ACR 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.